CPRX
Catalyst Pharmaceuticals Inc

15,817
Loading...
Loading...
News
all
press releases
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·10d ago
News Placeholder
More News
News Placeholder
Catalyst Pharmaceutical (CPRX) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·17d ago
News Placeholder
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·1mo ago
News Placeholder
Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin
CPRX secures a key win as its Firdapse patent litigation settlement with Lupin shields U.S. sales from generic competition until 2035.
Zacks·1mo ago
News Placeholder
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·2mo ago
News Placeholder
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks·2mo ago
News Placeholder
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.
Zacks·2mo ago
News Placeholder
Rigel Pharmaceuticals, Inc. (RIGL) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·2mo ago
News Placeholder
Catalyst (CPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·2mo ago
News Placeholder
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of +17.24% and +5.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago

Latest CPRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.